In phase 3, J&J's vaccine was 66% effective overall at preventing moderate-to-severe COVID-19
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.